

Uses of anti-VEGF in ophthalmology

Essay

Submitted for partial fulfillment of the MCs degree of ophthalmology

By

Amira Abdel fatah Abdel aziz

M.B.,B.CH.,ophthalmology

Cairo University

UNDER SUPERVISION OF

Prof.Dr.Ahmed Bahy Eldien Shalash

Professor of ophthalmology

Cairo University

Assist.prof.Dr.Mohamed Abdel Monaem Hassabalah

Assistant professor of ophthalmology

Cairo University

Faculty of medicine

Cairo University

2010

ACKNOWLEDGEMENT

I would like to express my gratitude to *Professor Dr.Ahmed Shalash* who meticulously supervised every minor and major detail in this work with concern and with lot of patience and valuable time .

My gratitude is to *Assistant Professor Dr.Mohamed Hasaballah* , for supervising this work and supporting me all through the different stages of this essay .

I would like to thank my dear parents, brother and sister as they supported me with ongoing care throughout this work .

Abstract

Ocular neovascularization may affect the retina, choroid, iris and cornea and is commonly seen in some of our most common sight-threatening eye diseases including diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity (ROP) and ischemic retinal vein occlusions. The advent of (VEGF) treatments marks a major advancement in the treatment of those angiogenic eye diseases.

KEY WORD

Neovascularization

Angiogenesis

Anti-VEGF

Index

Chapter 1 : Introduction .

Chapter 2 : Vascular endothelial growth factor.

Chapter 3 : Anti-vascular endothelial growth factor.

Chapter 4 : Anti-VEGF uses in CNV.

Chapter 5 : Anti-VEGF uses in age related macular degeneration.

Chapter 6 : Anti-VEGF uses in CNV 2ry to pathological myopia.

Chapter 7 :Anti-VEGF uses in CNV 2ry to angioid streaks.

Chapter 8 : Anti -VEGF uses in other causes of CNV.

Chapter 9 :Anti-VEGF uses in proliferative diabetic retinopathy.

Chapter 10:Anti -VEGF uses in retinal vein occlusions.

Chapter 11: Anti-VEGF uses in pediatric vitreoretinal diseases associated with neovascularization.

Chapter 12:Anti-VEGF uses in neovascular glaucoma.

Chapter 13: Anti -VEGF uses in corneal neovascularization.

Chapter 14: Anti -VEGF uses in pterygium .

Chapter 15:Anti-VEGF in other ocular diseases associated with neovascularisation.

Chapter 16:Complications of anti-VEGF.

Chapter 17: References.

List of abbreviations

AMD: Age Related Macular Degeneration.

ANCHOR : ANti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularization in AMD.

Anti-VEGF: Anti Vascular Endothelial Growth Factors.

AP-ROP : Aggressive Posterior ROP .

BCVA: Best Corrected Visual Acuity.

BEAT-ROP study: Bevacizumab Eliminates The Angiogenic Threat Of ROP.

CFT: Central Foveal Thickness.

CME: Cystoid Macular Edema.

CMT : Central Macular Thickness .

CNV : Choroidal Neovascularisation.

CO: Choroidal Osteoma.

Corneal NV: Corneal Neovascularization.

CRT: Central Retinal Thickness

CSDME: Clinically Significant Macular Edema.

DA : Disc Area

DRCR: Diabetic Retinopathy Clinical Research .

EBR : External Beam Radiation .

EPR : External Beam Radiation.

ETDRS: Early Treatment Diabetic Retinopathy Study Research.

FDA: Food and Drug Administration .

FEVR : Familial Exudative Vitreoretinopathy.

FOCUS :RhuFab V2 Ocular Treatment Combining the Use of Visudyne to Evaluate Safety .

GDI :Glaucoma Drainage Implant.

ICB: Intracameral Bevacizumab.

ICNV: Idiopathic Choroidal Neovascularisation.

IVB :Intravitreal Bevacizumab

IVTA : intravitreal triamcinolone .

MARINA :Minimally Classic/Occult Trial of Anti-VEGF Antibody RhuFab V2 in the Treatment of Neovascular AMD.

mCNV: Myopic Choroidal Neovascularisation.

MMC: Mitomycin C.

NVA: Neovascularization Of The Angle

NVD: Neovascularisation At Optic Disc.

NVE: Neovascularisation Elsewhere.

NVG : Neovascular Glaucoma.

NVI: Neovascularization Of The Iris

OHS : Ocular Histoplasmosis .

PAS: Peripheral Anterior Synichia.

PDR: Prolifrative Diabetic Retinopathy.

PDT : Photodynamic Therapy.

PED :Pigment Epithelial Detachment.

PEDF : Pigment Epithelium-Derived Factor .

PKP: Penetrating Keratoplasty.

PlGF : Placental Growth Factor .

PM : Pathological Myopia.

POHS : Presumed Ocular Histoplasmosis Syndrome .

PrONTO :Prospective OCT Imaging of Patients With Neovascular AMD Treated With Intraocular Lucentis.

PRP: Panretinal Photocoagulation.

PXE : Pseudoxanthoma Elasticum.

RN : Retinal Neovascularization.

RNAi : RNA interference .

RON: Radiation Optic Neuropathy.

ROP :Retinopathy of Prematurity.

RP:Retinitis Pigmentosa.

SAILOR :Safety Assessment of Intravitreal Lucentis for AMD trial.

SANA: Systemic Avastin For Neovascular Age Related Macular Degeneration .

siRNA : small interfering RNA.

SLO: Scanning Laser Ophthalmoscopy.

VEGF:Vascular Endothelial Growth Factors.

VHL :Von Hippel-Lindau.

VISION : VEGF Inhibition Study In Ocular Neovascularization.

ZO-1: zonula occludens 1 .

List of figures

Figure 1: diagram showing physiological & pathological effects of VEGF.

Figure 2: diagram showing structure of Lucentis & Avastin.

Figure 3&4: diagrams showing mechanism of action of anti-VEGF.

Figure 5&6: Color fundus photographs, fluorescein angiograms and OCT of patient 1&2 with an occult CNV with no classic CNV lesion at baseline and at months 12 and 24 after treatment with Ranibizumab in MARINA study. (Philip et al, 2006)

Figure 7&8: fundus fluorescein angiography showing pre & 12m post Ranibizumab injection results ANCHOR study. (David et al, 2006)

Figure 9: A&B fundus and FA images of a case receiving triple therapy including single-session photodynamic therapy (PDT), intravitreal bevacizumab (IVB) and intravitreal triamcinolone (IVTA) for treatment of neovascular (AMD). (Yip et al, 2009)

Figure 10: Fundus photography shows a pigmented CNV in macular region.

Figure 11: Fluorescein angiography and OCT pre and 3 months post intravitreal injection of bevacizumab in myopic CNV. (Yamamoto et al, 2007)

Figure 12: Color fundus photograph and late-phase FA of a case with myopic CNV without macular atrophy treated with 1mg intravitreal bevacizumab IVB. (Ikono et al, 2009)

Figure 13: Baseline fundus photograph & Last follow-up FA following intravitreal injection of 0.3mg ranibizumab in the treatment of myopic CNV. shows a marked reduction in size of the neovascular complex. (Lazaros et al, 2009)

Figure 14: Baseline and last follow-up visit; color fundus photographs. & Early phase FA following intravitreal injection of 0.3mg ranibizumab in the treatment of myopic CNV. (Lazaros et al, 2009)

Figure 15: Baseline OCTs & Last follow-up OCTs following intravitreal injection of 0.3mg ranibizumab in the treatment of myopic CNV.(Lazaros et al,2009)

Figure 16: colour photo & FA in pre & Eight months after a single intravitreal bevacizumab (1.25 mg/0.05 mL) injection in a case of CNV 2ry to angioid streaks (Pawan et al,2007)

Figure 17:BCVA given as the Snellen equivalent , Fundus photography &OCT fluorescein angiography pre &post intravitreal bevacizumab (1.5 mg/0.05 mL) injection in a case of CNV 2ry to angioid streaks. (Finger et al,2008)

Figure 18:Up figures: (FA) and (OCT) before treatment; Down figures: FA and OCT after four intravitreal injections of sodium pegaptanib (Macugen 0.3 mg/ 0.5 ml) with 6 weeks between injections. (Molina et al,2008)

Figure 19: FA before and 2 weeks after intravitreal injection of bevacizumab. (Yu-Chi et al,2009)

Figure 20:coloured fundus photo and OCT pre & 3monthes after intravitreal dose of 1.25 mg of bevacizumab in a patient with CNV 2r to POHS. (Alfredo et al ,2007)

Figure 21:Coloured fundus photograph ,late-phase fluorescein angiogram of peripapillary choroidal osteoma with CNV before &after 3months of two sessions of intravitreal 1.25 mg, 0.05 ml bevacizumab. (Won Kyung et al ,2009)

Figure 22: Indocyanine green angiography, early phase and late phase show hyperflouescent lesion on the border of Bruch's membrane rupture. Spectralis optical coherence confirm CNV with subretinal fluid . (Liang et al ,2009)

Figure 23: FA and OCT follow-up of CNV secondary to Bruch's membrane rupture before and 12-month after 0.5 mg/0.05 ml ranimizumab injection (Liang et al ,2009)

Figure 24: Infrared (IR) details of the superior-temporal multiple NVEs before and 1 month after the intravitreal bevacizumab injection . (Angelo et al,2008)

Figure 25 & 26: Wide-field contact Staurenghi lens fluorescein angiography before and 1 month after bevacizumab intravitreal injection. (Angelo et al,2008)

Figure 27: horizontal (OCT) scans before & after intravitreal injection of 2.5 mg bevacizumab. (Arevalo et al ,2007)

Figure 28: Fundus appearance 1 week after intravitreal injection of 1.25 mg bevacizumab and just before vitrectomy (A), postoperative appearance 2 months after surgery (B). (Avery et al,2008)

Figure 29: Red-free (A), midphase (B), and late-phase (C) angiograms at baseline and 3 weeks after intravitreal injection of 1.25 mg of bevacizumab. (Avery et al,2008)

Figure 30: Color, red free , midphase, and late-phase fluorescein angiograms at (A) baseline and (B) 1 week after intravitreal injection of 1.25 mg of bevacizumab. (Avery et al,2008)

Figure 31: FA and OCT before & after bevacizumab injections in a patient with CRVO. (Beutel et al,2008)

Figure 32 : cystoid macular oedema secondary to central retinal vein occlusion. The patient received six injections at baseline, month 1, month 2, month 6, month 9 and month 11. CRT, central retinal thickness decreased as shown in OCT. (Prager et al,2009)

Figure 33 : cystoid macular oedema secondary to branch retinal vein occlusion. The patient received four injections at baseline, month 1, month 2 and at month 3. CRT, central retinal thickness decreased as shown in OCT & FA . (Prager et al,2009)

Figure 34: stages of ROP. (Kanski,2007)

Figure 35: Intravitreal Avastin for Zone I ROP on an infant who was 550 g and 24 weeks gestational age at birth . (Mintz-Hittner,2009)

Figure 36 & 37: Histological characteristics and apoptotic activity in postmortem eyes after injection by bevacizumab. (Kong et al,2008)

Figure 38: stages of neovascular glaucoma (Kanski and Salmon,2007)

Figure 39-a: Fundus photography of the left eye showing the juxtapapillary melanoma located in the nasal inferior quadrant and the persisting serous retinal detachment with subretinal exudates. **39-b:** One

hour before the intravitreal injection of ranibizumab, iris angiography showed massive leakage of iris vessels (58.2 s after intravenous injection of 5 mL of 10% sodium fluorescein). **39-c:** Two days after the injection massive improvement of the rubeosis was documented (iris angiogram 61.3 s after intravenous sodium fluorescein injection). (Dunavoelgyi et al, 2007)

Figure 40-a: Fluorescein angiography revealed hypofluorescence in the choroid and retinal vessels **Fig(40 -b).** Slit lamp examination demonstrated rubeosis iridis. **Fig(40-c)** One day after intravitreal injection of bevacizumab, neovascularization of the iris had almost completely resolved. (Lee et al, 2009)

Figure 41 : Neovascular membrane (NVM) covering the iris surface before bevacizumab injection (A), regression of NVM 1 week after bevacizumab treatment (B), and gonioscopy showing involution of the NVM (C and D). Case 2: Regression of the NVM over the iris collarette during the first week after intracameral injection of bevacizumab (E and F) and as compared with preoperative caliber of new vessels (G) marked reduction of the caliber on the first postoperative day (H) with complete disappearance by the first week (I). Case 5: Preoperative and postoperative neovascularization on the iris surface and anterior chamber angle, with complete regression within the first week after bevacizumab injection (J–M). Case 4: After involution of NVM as a result of bevacizumab therapy (N–P), cataract phacoemulsification with intraocular lens implantation and the double-plate Molteno drainage implant located below the iridectomy could be performed without complications (Q). (Duch et al, 2009)

Figure 42: before and 1 month after subconjunctival bevacizumab injection revealing regression of corneal NV and pseudopterygium (Priyanka et al, 2008)

Figure 43 : Pre- and post bevacizumab injection photographs of patients 1 (A–C) and 2 (D–F). (Joo Youn et al, 2009)

Figure 44: (a) Photograph of patient #7 prior to PKP and bevacizumab application—marked neovascularization is seen, especially superiorly and nasally. (b) Photograph of the same patient 2 months after PKP and bevacizumab application, showing dramatic reduction of corneal NV (Vassileva and Hergeldzhieva, 2009)

Figure 45: (a) Photograph of patient #10 with initial graft rejection and superficial vascularization advancing towards the graft–host junction

before bevacizumab application (b)Photograph of the same patient 1 month after bevacizumab application, showing regressed graft oedema, no progression of the rejection line, and disappearance of corneal NV (Vassileva and Hergeldzhieva,2009)

Figure 46 : Patient 1. A, The patient's cornea is shown prior to topical bevacizumab treatment, displaying extensive neovascular vessels, most evident inferiorly.B, Dramatic reduction in vascularization resulted after 25 days of topical therapy. (Destafeno and kim,2007)

Figure 47: Patient 2. A, The patient's cornea is shown prior to topical bevacizumab treatment, displaying neovascular vessels, scarring, and band keratopathy.B, Reduction in vascularization resulted after 25 days of topical therapy. (Destafeno and kim,2007)

Figure 48: The effect of topical bevacizumab in patient 6, One (B), 6 (C), and 24 (D) weeks after topical bevacizumab treatment. significant therapeutic response, evidenced as early as 1 week after initiation of anti-VEGF treatment. (Dastjerdi et al,2009)

Figure 49: (a) Case 1. Pterygium bed of the left eye displays elevated fibrovascular mass with a high count of microvessels.(b)Case 1. One week after subconjunctival ranibizumab (0.1 ml or 1 mg) , the pterygium bed appears flattened with attenuation of conjunctival vessels. This appearance was unchanged 13 months after the injection. (Mansour et al ,2009)

Figure 50: (a)Case 2. The residual pterygium of the right eye was markedly injected following excision of the advancing edge of the pterygium at the end of phacoemulsification. Note the high count of conjunctival microvessels.(b) Case 2. One week after subconjunctival bevacizumab (0.1 ml or 2.5 mg), the injection disappeared in the residual pterygium bed. (Mansour et al ,2009)

Figure 51 : A.colour photograph of Patient 5 demonstrating typical arteriolar attenuation, retinal bone-spicule pigmentation, and maculopathy. B.Early phase of intravenous fluorescence angiography shows hyperfluorescence without leakage at fovea.C.Baseline OCT of the patient shows foveal thickening and cystoid macular edema(Yuzbasioglu et al,2009).

Figure 52: Composite of color and fluorescein angiographic images over time. A, Case 1: prior to bevacizumab treatment, the color photograph reveals retinal,hemorrhages, exudates, and intraretinal microangiopathy. B, The corresponding early fluorescein angiogram reveals macular

edema, capillary nonperfusion, microaneurysms, and focal leakage of neovascular vessels. C, Three months after treatment with intravitreal bevacizumab, a color photograph reveals decreased hemorrhages and exudates. D, The corresponding fluorescein angiogram shows markedly decreased macular edema, decreased intraretinal microangiopathy, and leakage (sharpening of vessel walls). (Paul et al,2007)

Figure 53:A, The melanoma occupied the inferior portion of the iris and diffuse NV on the entire iris surface was noted. B, Ultrasound biomicroscopy depicted a solid iris mass touching the endothelium . Treatment involved intravitreal bevacizumab and plaque radiotherapy. C, Application of the radioactive plaque over the cornea for a total dose of 8000 cGy to the melanoma (the conversion of centigray to rad is 1:1). D,Fifteen months after treatment, the tumor remained regressed and the NVI completely resolved. A dense cataract is present. Cataract surgery is planned. (Bianciotto et al,2008)

Figure 1: diagram showing physiological & pathological effects of VEGF

Figure 2: diagram showing structure of Lucentis & Avastin.

Figure 3&4: diagrams showing mechanism of action of anti-VEGF.

Figure 5&6: Color fundus photographs, fluorescein angiograms and OCT of patient 1&2 with an occult with no classic CNV lesion at baseline and at months 12 and 24 after treatment with Ranibizumab in MARINA study.

Figure 7&8: fundus fluorescein angiography showing pre & 12m post Ranibizumab injection results ANCHOR study.

Figure 9: A&B fundus and FA images of a case receiving triple therapy including single-session photodynamic therapy (PDT), intravitreal bevacizumab (IVB) and intravitreal triamcinolone (IVTA) for treatment of neovascular (AMD).

Figure 10: Fundus photography shows a pigmented CNV in macular region.

Figure 11: Fluorescein angiography and OCT pre and 3 months post intravitreal injection of bevacizumab in myopic CNV. (Yamamoto et al, 2007)

Figure 12: Color fundus photograph and late-phase FA of a case with myopic CNV without macular atrophy treated with 1mg intravitreal bevacizumab IVB. (Ikono et al, 2009)

Figure 13: Baseline OCTs & Last follow-up OCTs following intravitreal injection of 0.3mg ranibizumab in the treatment of myopic CNV.

(Lazaros et al, 2009)

Figure 14: Baseline and last follow-up visit; color fundus photographs. & Early phase FA following intravitreal injection of 0.3mg ranibizumab in the treatment of myopic CNV. (Lazaros et al, 2009)

Figure 15: Baseline fundus photograph & Last follow-up FA following intravitreal injection of 0.3mg ranibizumab in the treatment of myopic CNV. shows a marked reduction in size of the neovascular complex. (Lazaros et al, 2009)

Figure 16: colour photo & FA in pre & Eight months after a single intravitreal bevacizumab (1.25 mg/0.05 mL) injection in a case of CNV 2ry to angioid streaks (Pawan et al,2007)

Figure 17:BCVA given as the Snellen equivalent , Fundus photography &OCT fluorescein angiography pre &post intravitreal bevacizumab (1.5 mg/0.05 mL) injection in a case of CNV 2ry to angioid streaks. (Finger et al,2008)

Figure 18:Up figures: (FA) and (OCT) before treatment; Down figures: FA and OCT after four intravitreal injections of sodium pegaptanib (Macugen 0.3 mg/ 0.5 ml) with 6 weeks between injections. (Molina et al,2008)

Figure 19: FA before and 2 weeks after intravitreal injection of bevacizumab. (Yu-Chi et al,2009)

Figure 20:coloured fundus photo and OCT pre & 3monthes after intravitreal dose of 1.25 mg of bevacizumab in a patient with CNV 2r to POHS. (Alfredo et al ,2007)

Figure 21:Coloured fundus photograph ,late-phase fluorescein angiogram of peripapillary choroidal osteoma with CNV before &after 3months of two sessions of intravitreal 1.25 mg, 0.05 ml bevacizumab. (Won Kyung et al ,2009)

Figure 22: Indocyanine green angiography, early phase and late phase show hyperflourescent lesion on the border of Bruch's membrane rupture. Spectralis optical coherence confirm CNV with subretinal fluid . (Liang et al ,2009)

Figure 23: FA and OCT follow-up of CNV secondary to Bruch's membrane rupture before and 12-month after 0.5 mg/0.05 ml ranimizumab injection (Liang et al ,2009)

Figure 24: Infrared (IR) details of the superior-temporal multiple NVEs before and 1 month after the intravitreal bevacizumab injection .

(Angelo et al,2008)

Figure 25 &26: Wide-field contact Staurenghi lens fluorescein angiography before and 1 month after bevacizumab intravitreal injection. (Angelo et al,2008)

Figure 27: horizontal (OCT) scans before &after intravitreal injection of 2.5 mg bevacizumab. (Arevalo et al ,2007)